Business Wire

IDEMIA Will Present Its H1 2021 Financial Results to Investors on July 27, 2021

Share

IDEMIA, the world leader in Augmented Identity, today announced that it will present its H1 2021 financial results to investors on Tuesday July 27, 2021.

Pierre Barrial (President & CEO) and Didier Fontaine (COO/CFO) will be presenting the financial results and taking questions the same day at 4:00 pm CET (3:00 pm London Time / 10:00 am New York Time).

For more information, please refer to our website: https://investors.idemia.com/

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
Hanna Sebbah
+33 6 63 73 30 30
idemia@havas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*21.9.2021 14:45:00 EEST | Press release

PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE FOR MEDICAL BUSINESS / HEALTHCARE INDUSTRY TRADE MEDIA ONLY Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva®, (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3 Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have

Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls21.9.2021 14:00:00 EEST | Press release

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s health. Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls. Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scor

CBRE GLOBAL INVESTORS JULKAISEE EUROPEAN RESIDENTIAL IMPACT FUNDIN NELJÄN SIJOITTAJAN TEKEMÄLLÄ 465 MILJOONAN EURON PÄÄOMASITOUMUKSELLA21.9.2021 13:52:00 EEST | Tiedote

Tämä on markkinointiviesti. Tutustu CBRE European Residential Impact Fund S.C.A. SICAV-SIFin perustamiskirjaan ennen lopullisten sijoituspäätösten tekemistä. Tämän julkaisun kautta ei tehdä tarjousta yhdysvaltalaisille sijoittajille. Tämä julkaisu ei muodosta tarjousta myydä tai ostaa CBRE European Residential Impact Fund S.C.A. SICAV-SIFin osakkeita tai mitään muuta tuotetta, eivätkä yhdysvaltalaiset sijoittajat voi käyttää sitä tai tukeutua siihen tehdessään sijoituspäätöksiä. Kaikki tarjoukset tehdään vain luottamuksellisen perustamiskirjan ja siihen liittyvän tilaussopimuksen kautta, jotka toimitetaan vain päteville sijoittajille. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20210921005579/fi/ Paul Oremus, CBRE European Residential Impact Fundin rahastonhoitaja (Photo: Business Wire) CBRE Global Investors, joka on yksi maailman johtavia kiinteän omaisuuden hoitoyhtiöitä, ilmoittaa tänään CBRE European Residential Impa

FourKites Names 60+ Customers as Innovation Partners to Accelerate Supply Chain Innovation and Increase Business Value21.9.2021 13:49:00 EEST | Press release

FourKites®, the world’s leading real-time supply chain visibility platform, today welcomed more than 60 customers into its formal Innovation Partner program, designed to accelerate customer-driven innovation and shape the future of digital supply chains. The first formal cohort of Innovation Partners includes Henkel, AB InBev, Cardinal Health, Ecolab, Kimberly-Clark, Meijer, Smithfield, Canadian Forest Products and Andersen Corporation, among others. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005575/en/ FourKites® today welcomed more than 60 customers into its formal Innovation Partner program, designed to accelerate customer-driven innovation and shape the future of digital supply chains. (Graphic: Business Wire) FourKites’ leading community of global shippers, freight forwarders and 3PLs have long been active contributors and co-innovators in FourKites’ solutions and product roadmap. The establishment of the Inno

Cybercriminal Attacks Accelerate Global Cybersecurity Crisis According to 1H2021 NETSCOUT Threat Intelligence Report21.9.2021 13:00:00 EEST | Press release

NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report that underscore the dramatic impact cyberattacks continue to have on private and public organizations and governments worldwide. In the first half of 2021, cybercriminals launched approximately 5.4 million Distributed Denial of Services (DDoS) attacks, increasing 11% over 1H2020 figures. Additionally, data projections from NETSCOUT's Active Level Threat Analysis System (ATLAS™) Security Engineering and Response Team (ASERT) point to 2021 as another record-setting year on track to surpass 11 million global DDoS attacks. ASERT expects this long tail of attacker innovation to last, fueling a growing cybersecurity crisis that will continue to impact public and private organizations. In the wake of Colonial Pipeline, JBS, Harris Federation, Australian broadcaster Channel Nine, CNA Financial, and several other high-profile attacks, the impact of DDoS and other cybersecurity attacks h

Clinical Investigation Shows Herb-Pharma's ViroStop Spray Effective in Reducing Impact of Covid-1921.9.2021 13:00:00 EEST | Press release

A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms. The key benefits were a 60% reduction in viral shedding after using the treatment and a reduction in the severity of clinical respiratory symptoms. The study supports the findings of earlier in-vitro tests where its mix of polyphenols inhibited the growth of the virus in cell cultures. The study included 170 PCR confirmed SARS-CoV-2 patients at the Complex Medical Clinic in Budapest, Hungary between January 15th, and May 31st, 2021. The volunteers all had mild to moderate respiratory symptoms, having tested positive in PCR tests for Covid-19 at the start of the study, and their symptoms were monitored over 12 days. Of the 170 volunteers, 86 received a nasopharyngeal spray, the patented ViroStop solution, which contains a mixture of Cistus Creticus and other polyphenol-rich ingredients. Polypheno

Biedermann Motech To Further Expand MOSS VRS® - The Next Generation Pedicle Screw Technology™ By Adding MOSS Modularity™21.9.2021 13:00:00 EEST | Press release

Biedermann Motech, the company that developed the world’s first polyaxial pedicle screw (MOSS® System) and pioneer in the spinal market for more than 35 years, today announced that its MOSS VRS® Pedicle Screw Platform, the most advanced system on the market today, is now available as a fully modular solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005274/en/ The Next Generation: MOSS VRS®. Real-Time Intraoperative Decision Making. (Graphic: Business Wire) The MOSS VRS System features Next Generation Pedicle Screw Technology™, which allows the surgeon to lock the polyaxial angle of the pedicle screw at any angle, at any time during surgery. This provides surgeons unmatched intraoperative real-time options using a single, highly functional implant. In contrast to traditional pedicle screw systems, which include a wide range of different screw types, the MOSS VRS Pedicle Screw can be locked and unlocked as and whe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom